



University of
Zurich^{UZH}

Zurich Open Repository and
Archive

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2024

Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

Abela, Irene A ; Hauser, Anthony ; Schwarzmüller, Magdalena ; Pasin, Chloé ; Kusejko, Katharina ; Epp, Selina ; Cavassini, Matthias ; Battegay, Manuel ; Rauch, Andri ; Calmy, Alexandra ; Notter, Julia ; Bernasconi, Enos ; Fux, Christoph A ; Leuzinger, Karoline ; Perreau, Matthieu ; Ramette, Alban ; Gottschalk, Jochen ; Schindler, Eméry ; Wepf, Alexander ; Marconato, Maddalena ; Manz, Markus G ; Frey, Beat M ; Braun, Dominique L ; Huber, Michael ; Günthard, Huldrych F ; Trkola, Alexandra ; Kouyos, Roger D ; Swiss HIV Cohort Study

DOI: <https://doi.org/10.1093/infdis/jiae002>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-257077>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Abela, Irene A; Hauser, Anthony; Schwarzmüller, Magdalena; Pasin, Chloé; Kusejko, Katharina; Epp, Selina; Cavassini, Matthias; Battegay, Manuel; Rauch, Andri; Calmy, Alexandra; Notter, Julia; Bernasconi, Enos; Fux, Christoph A; Leuzinger, Karoline; Perreau, Matthieu; Ramette, Alban; Gottschalk, Jochen; Schindler, Eméry; Wepf, Alexander; Marconato, Maddalena; Manz, Markus G; Frey, Beat M; Braun, Dominique L; Huber, Michael; Günthard, Huldrych F; Trkola, Alexandra; Kouyos, Roger D; Swiss HIV Cohort Study (2024). Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study. *Journal of Infectious Diseases*:Epub ahead of print.

DOI: <https://doi.org/10.1093/infdis/jiae002>

Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study

Irene A. Abela,^{1,2,a} Anthony Hauser,^{1,2,a} Magdalena Schwarz Müller,^{2,a} Chloé Pasin,^{1,2,3,a} Katharina Kusejko,^{1,2} Selina Epp,² Matthias Cavassini,⁴ Manuel Battegay,⁵ Andri Rauch,⁶ Alexandra Calmy,⁷ Julia Notter,⁸ Enos Bernasconi,⁹ Christoph A. Fux,¹⁰ Karoline Leuzinger,¹¹ Matthieu Perreau,¹² Alban Ramette,¹³ Jochen Gottschalk,¹⁴ Eméry Schindler,¹⁴ Alexander Wepf,¹⁵ Maddalena Marconato,¹⁶ Markus G. Manz,¹⁶ Beat M. Frey,¹⁴ Dominique L. Braun,¹ Michael Huber,² Huldrych F. Günthard,^{1,2,b} Alexandra Trkola,^{2,b} and Roger D. Kouyos^{1,2,b}, and the Swiss HIV Cohort Study

¹Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; ²Institute of Medical Virology, University of Zurich, Zurich, Switzerland; ³Collegium Helveticum, Zurich, Switzerland; ⁴Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland; ⁵Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland; ⁶Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland; ⁷Laboratory of Virology and Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Geneva, Switzerland; ⁸Division of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland; ⁹Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland; ¹⁰Department of Infectious Diseases, Kantonsspital Aarau, Aarau, Switzerland; ¹¹Clinical Virology, University Hospital Basel, Basel, Switzerland; ¹²Division of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; ¹³Institute for Infectious Diseases, University of Bern, Bern, Switzerland; ¹⁴Blood Transfusion Service Zurich, Zurich, Switzerland; ¹⁵Institute of Laboratory Medicine, Cantonal Hospital Winterthur, Winterthur, Switzerland; and ¹⁶Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland

Background. Factors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency virus (HIV) and serologic assessment for SARS-CoV-2 and circulating human coronavirus (HCoV) antibodies, we investigated the association of HIV-related and general parameters with SARS-CoV-2 infection.

Methods. We analyzed SARS-CoV-2 polymerase chain reaction test results, COVID-19-related hospitalizations, and deaths reported to the Swiss HIV Cohort Study between 1 January 2020 and 31 December 2021. Antibodies to SARS-CoV-2 and HCoVs were determined in pre-pandemic (2019) and pandemic (2020) biobanked plasma samples and compared with findings in HIV-negative individuals. We applied logistic regression, conditional logistic regression, and bayesian multivariate regression to identify determinants of SARS-CoV-2 infection and antibody responses to SARS-CoV-2 in people with HIV.

Results. No HIV-1-related factors were associated with SARS-CoV-2 acquisition. High pre-pandemic HCoV antibodies were associated with a lower risk of subsequent SARS-CoV-2 infection and with higher SARS-CoV-2 antibody responses on infection. We observed a robust protective effect of smoking on SARS-CoV-2 infection risk (adjusted odds ratio, 0.46 [95% confidence interval, .38–.56]; $P < .001$), which occurred even in previous smokers and was highest for heavy smokers.

Conclusions. Our findings of 2 independent protective factors, smoking and HCoV antibodies, both affecting the respiratory environment, underscore the importance of the local immune milieu in regulating susceptibility to SARS-CoV-2.

Keywords. SARS-CoV-2; HIV; preexisting immunity; endemic human coronaviruses; smoking.

Identifying factors that influence the acquisition, transmission, severity, prevention, and treatment of SARS-CoV-2 infection relies on comprehensive sources of health, behavioral,

epidemiologic, and socioeconomic data. Prospective, large-scale, longitudinal cohort studies can provide this type of data, enabling critical public health research [1–3]. Human immunodeficiency virus (HIV) cohorts provide a unique opportunity in resolving interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), HIV-1, and other comorbid conditions [4–6]. Coronavirus disease 2019 (COVID-19) seriously affects particularly vulnerable populations, including people with advanced age, comorbid conditions, or immunosuppression [7–9]. Accordingly, HIV-1 has been identified as a potential risk factor that may exacerbate COVID-19 disease, especially if HIV-1 infection is not effectively treated [10–13]. Immune responses to infections and vaccines often remain reduced in people with HIV (PWH) even with suppressive antiretroviral treatment (ART) [14–16]. This may also affect the course of SARS-CoV-2 infection in PWH, since decreased antibody responses to

Received 20 July 2023; editorial decision 02 January 2024; accepted 04 January 2024; published online 16 January 2024

^aI. A. A., A. H., M. S., and C. P. contributed equally to this work.

^bH. F. G., A. T., and R. D. K. contributed equally to this work.

Correspondence: Irene A. Abela, MD, PhD, Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland (irene.abela@usz.ch).

The Journal of Infectious Diseases®

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com
<https://doi.org/10.1093/infdis/jiae002>

SARS-CoV-2 infection have been linked with slower clearance of SARS-CoV-2 [17]. Understanding whether and how HIV-1 positivity affects SARS-CoV-2 susceptibility and outcome is therefore important.

Here we report on a comprehensive systematic investigation of the interactions of HIV-1 and SARS-CoV-2 infection within the Swiss HIV Cohort Study (SHCS) [3] during the initial waves of the SARS-CoV-2 pandemic in Switzerland. The SHCS is highly representative of PWH living in Switzerland [3]. With its longitudinal study design, plasma and blood cell biobank, and comprehensive demographic data, including HIV-related as well as general health, behavioral, and epidemiology parameters, the SHCS provides a large data resource with opportunities to address public health concerns beyond HIV infection [18, 19]. While residual immune suppression in antiretroviral-treated PWH is a potential concern, most SHCS participants are fully virologically suppressed, comparatively healthy, and immunologically stable [3]. Accordingly, investigation of determinants of SARS-CoV-2 infection within the SHCS may also provide insights relevant for the general population. In support, the prevalence of SARS-CoV-2 infections in PWH has been found to be similar to the general population [20–23], and virologically suppressed PWH respond well to SARS-CoV-2 vaccines [24, 25]. In the current study, we explored the epidemiology of SARS-CoV-2 waves in Switzerland from 2020–2021 among PWH compared with the general Swiss population and determined the parameters associated with SARS-CoV-2 infection in both populations.

METHODS

Study Population and Ethics

Study Population With HIV

The SHCS is a prospective PWH cohort with semiannual visits and blood collections [3]. Detailed information is available online (<http://www.shcs.ch>). The SHCS is registered under the Swiss National Science longitudinal platform [26] and has been approved by the ethics committee of the participating institutions (Supplementary Material 1.1). Written informed consent had been obtained from all participants. In March 2020, a SARS-CoV-2 questionnaire was introduced into the SHCS, resulting in 7073 assessments of whether participants had a polymerase chain reaction (PCR) test for SARS-CoV-2, whether that test result was positive, and whether participants were hospitalized for COVID-19 (see flowchart in Supplementary Figure 1).

Study Population Without HIV

We included a population of 382 HIV-uninfected (HU) individuals with PCR-confirmed SARS-CoV-2 infections from 2 prior SARS-CoV-2 studies [17, 27] with published AntiBody

CORonavirus Assay (ABCORA) serology data (Supplementary Material 1.2; Supplementary Table 1). Published epidemiology data from the Swiss Federal Office of Public Health on the number of SARS-CoV-2 cases, hospitalizations, and deaths were used to compare these outcomes between PWH and the general Swiss population [28].

SARS-CoV-2 Serology

SARS-CoV-2 serology was performed on biobanked SHCS plasma samples with the ABCORA 5 assay [27]. ABCORA 5 determines antibody binding for each of the 3 immunoglobulin (Ig) classes—IgA, IgG, and IgM—as the median fluorescence intensity (MFI) against 4 SARS-CoV-2 antigens (S1 subunit, S2 subunit, nucleocapsid protein [N], and receptor-binding domain [RBD]) and the S1 subunits of the 4 endemic human coronaviruses (HCoVs) (HCoV-OC43, HCoV-NL63, HCoV-HKU1, and HCoV-229E). MFI values were normalized relative to empty bead controls yielding binding strengths quantified as MFI–log-fold over empty (MFI-LFOE). We used the previously calibrated random-forest-based ABCORA 5.4 algorithm to infer SARS-CoV-2 seropositivity based on the SARS-CoV-2 MFI-LFOE values.

HCoV Testing

Routine diagnostic analyses of respiratory samples for the endemic HCoVs (HCoV-OC43, HCoV-NL63, HCoV-HKU1, and HCoV-229E) were performed with multiplex respiratory PCR panels (ePlex RP [Roche] or BioFire RP2.1 [BioMérieux]). Repetitive tests of the same patient within 20 days of the initial positive result were excluded.

Assessing the Impact of Prepandemic HCoV Response in a Matched PWH Case-Control Study

We conducted a 1:2 matched nested case-control study in selected PWH from the SHCS to assess the impact of prior existing HCoV-specific antibodies on the risk of SARS-CoV-2 infection. For this we retrieved prepandemic plasma samples for all SARS-CoV-2-infected case patients and matched controls from 2019 from the SHCS biobank and measured their HCoV antibody levels using ABCORA 5 (Supplementary Figure 2A and 2B).

Statistical Analysis

To assess risk factors for acquiring SARS-CoV-2, we used logistic regression models with SARS-CoV-2 infection as an outcome (ie, having either a positive PCR or a positive ABCORA serologic result) and included a wide range of demographic, behavioral, and disease variables documented in the SHCS database as explanatory variables (Figure 1, Supplementary Table 2, and Supplementary Material 1.6).

To assess the impact of prepandemic HCoV immunity on the risk of SARS-CoV-2 infection, we conducted a time-




Figure 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surveillance in Swiss HIV Cohort Study (SHCS) and the Swiss population. *A*, Schematic overview of the determinants of SARS-CoV-2 infections recorded in the SHCS. *B*, SARS-CoV-2 cases in Switzerland, as reported by the Swiss Federal Office of Public Health over time and waves of variants of concern. *C*, Numbers of self-reported polymerase chain reaction (PCR) and serologic tests performed in the SHCS, displayed by month and stratified by result. *D*, Test positivity in the SHCS (blue) and the Swiss population (black), by month. Dots represent the mean estimate, while the shaded area represents the 95% confidence interval, assuming a binomial distribution. Abbreviations: HCoV, human coronavirus; HIV, human immunodeficiency virus; Ig, immunoglobulin; RBD, receptor-binding domain; WT, wild type.

updated survival analysis [29], adjusted for age, sex, center, race/ethnicity, smoking status, and sampling time. We analyzed the data from the matched case-control study using a conditional logistic regression to estimate the risk of SARS-CoV-2 seropositivity. For each HCoV antigen, we defined the exposure variables by first summing the reactivities of IgG, IgA, and IgM and then stratifying these composite reactivities by the median into 2 groups (low vs high reactivity). We used linear univariate and multivariate regression models to compare SARS-CoV-2 antibody responses in PWH ($n=43$) and HU individuals ($n=382$) with PCR-confirmed SARS-CoV-2 infection and analogously to analyze HCoV antibody responses among the 453 PWH

with ABCORA 5 measurements in 2019 (Supplementary Material 1.5). Statistical analysis was conducted using R software, version 4.1.2 [30].

RESULTS

Factors that influence the highly variable susceptibility to SARS-CoV-2 infection and disease severity, particularly those that result in asymptomatic disease, have not been fully elucidated [31, 32]. The SHCS [3], through its prospective, longitudinal design and systematic collection of HIV-specific and general health parameters along with behavioral and socioeconomic factors, provided us with a unique opportunity for systematic investigation of factors associated with SARS-CoV-2

acquisition. By January 2020, the SHCS database comprised >300 parameters that were either self-reported or obtained from clinical records at the semiannual study visits [3]. Here, we investigated the effect of 25 specific parameters on susceptibility to SARS-CoV-2 infection based on their potential significance for the general population, as well as their influence on the interaction between HIV-1 infection and SARS-CoV-2 infection (Figure 1A and Supplementary Table 2).

To enable SARS-CoV-2 population studies, the SHCS database included information on SARS-CoV-2 PCR testing from April 2020 onward and information on vaccination following its availability in Switzerland. We focused in the present analysis on the period between 1 February 2020 and 31 December 2021, to cover the initial waves of the SARS-CoV-2 epidemic in Switzerland in a SARS-CoV-2 naive population and later on the onset of vaccination (Figure 1B–1D). During this period, 10 301 PWH were actively enrolled in the SHCS, and 4241 reported SARS-CoV-2 PCR results, of which 1009 were positive. During the first wave in 2020, PCR testing was not yet widely performed in Switzerland (Figure 1B and 1C) [33]. To improve SARS-CoV-2 prevalence assessment during this period, we performed SARS-CoV-2 multifactorial seroprofiling [27] of SHCS biobanked plasma samples from 2020 ($n = 3633$) (Figure 1C).

Retrospectively, 120 plasma samples were scored as SARS-CoV-2 positive. Combining SARS-CoV-2–positive PCR results (2020–2021) and seropositive serology results (2020), we obtained information on the SARS-CoV-2 status of 6270 SHCS participants. Of these, 1088 (17%) were rated as SARS-CoV-2 positive (Figure 1C and 1D and Supplementary Table 1 [demographics of the study cohort], and Supplementary Figure 1 [flowchart]). These 6270 PWH with known SARS-CoV-2 status were used as the full study cohort (Supplementary Figure 1). Importantly, SARS-CoV-2 test positivity in the SHCS reflected the SARS-CoV-2 waves in the Swiss population, as recorded by the Federal Office of Public Health (Figure 1D) [28].

No Impact of HIV-Related Factors on the Risk of SARS-CoV-2 Acquisition

We explored factors influencing susceptibility to SARS-CoV-2 infection by analyzing 16 diverse parameters, including variables that apply to the general population as well as HIV-related biomarkers (Figure 2A). We found that HIV-1 viral load and CD4⁺ T-cell levels, were not associated with SARS-CoV-2 infection risk in our well-treated cohort (96% PWH with undetectable HIV RNA in plasma; Supplementary Table 3). Several antiretroviral drugs, including the nucleotide inhibitor tenofovir and the protease inhibitors lopinavir and darunavir, have been controversially discussed to protect against SARS-CoV-2 infection [5, 34, 35]. We observed no

evidence for a reduced SARS-CoV-2 infection risk with these antiretrovirals (Figure 2A).

Influence of Health and Demographic Factors

SARS-CoV-2 vaccination had a protective effect for SARS-CoV-2 infection for the full study cohort (adjusted odds ratio [aOR], 0.51 [95% confidence interval [CI], .37–.7]) and when restricted to the 2021 subcohort (aOR, 0.49 [95% CI, .36–.68]) when vaccines became widely available (Figure 2A and Supplementary Tables 5 and 6). We found no effect of age or sex on acquisition of SARS-CoV-2 (Figure 2 and Supplementary Figures 3 and 4), except for age >65 years, which was associated with a lower risk, likely reflecting increased use of protective measures in this age group. Combined analysis of 6 comorbid conditions showed no effect on SARS-CoV-2 infection (Figure 2A), but individual analysis revealed a modest protective trend of drugs for obstructive airway diseases (Supplementary Figure 5). Interestingly, the frequency of SARS-CoV-2 infection differed by race/ethnicity, with a significantly increased infection risk in black participants (aOR, 1.4 [95% CI, 1.1–1.7]) in the full study cohort. The effect was stronger in the 2020 subcohort but faded in 2021 (Figure 2A).

Influence of Behavioral Factors

HIV acquisition risk groups did not show differential SARS-CoV-2 risk (Figure 2A and Supplementary Table 5). However, we observed a lower risk of infection among people living in single-person households (aOR, 0.77 [95% CI, .66–.9]) in 2021, but not in 2020 (Figure 2A). We attribute this to the gradual relaxation of mask wearing and social distancing in 2021, combined with the arrival of the higher-transmissible variants of concern Alpha and Delta in Switzerland (Figure 1 and [28]). It is plausible that living in a single-person household during these periods of higher infection rates reduced the likelihood of transmission.

Cigarette smoking had a significant effect on SARS-CoV-2 infection over all time periods studied (Figure 2A and 2B) (aOR, 0.49 [95% CI, .41–.59]), even with correction for a range of factors, including the intake of drugs for obstructive airway disease (Supplementary Figure 5), an indirect indicator for ruled underlying chronic lung disease. We therefore rated this finding (and in particular the strength of the effect) as highly unexpected and performed a series of sensitivity analyses. We ruled out confounding effects of a potential differential sensitivity of serology and PCR tests in smokers by stratifying the analyses per test type and test period (Supplementary Figures 3, 6, and 7). A negative association with SARS-CoV-2 infection among smokers persisted regardless of whether the entire study period or individual years were considered, or of whether SARS-CoV-2 infection was diagnosed by means of PCR or serology (Supplementary Figures 6 and 7).




Figure 2. Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition. *A*, Univariate and multivariate analysis of SARS-CoV-2 infection (determined by either polymerase chain reaction [PCR] or serology) risk factors adjusted for the depicted covariables and calendar time (included as cubic spline) and stratified by calendar time. The exposure variable comorbid conditions was defined as reports of either diagnoses (eg, hypertension and diabetes), risk factors (body mass index >35 [calculated as weight in kilograms divided by height in meters squared]), or the use of drugs related to comorbid conditions (immunosuppressive drugs, corticosteroids, or drugs for obstructive airway diseases). Numerical values of the odds ratio (OR; [Supplementary Table 5](#)) and a summary of population characteristics ([Supplementary Table 6](#)) are displayed in the [Supplementary Materials](#). *B*, Univariate and multivariate analysis of the dose-dependent effect of smoking on the risk SARS-CoV-2 infection (determined by either PCR or serology). Dots correspond to effect sizes; lines, to 95% confidence intervals. Abbreviations: ART, antiretroviral therapy; DRV, darunavir; Het, heterosexual; HIV, human immunodeficiency virus; IDU, injection drug use; LPV, lopinavir; MSM, men who have sex with men; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate; VL, viral load (copies/mL).

The effect of smoking also remained robust when additional potential confounders were included, such as alcohol ([Supplementary Figure 8](#)) and marijuana use ([Supplementary Figure 9](#)), or when behavioral variables were expanded to include heavy physical work, having a stable partner, or having an occasional partner ([Supplementary Figure 10](#)). None of these variables had an effect by themselves, with the exception

of having occasional partners, which was associated with a higher infection risk (aOR, 1.27 [95% CI, 1.05–1.55]). In support of a direct effect of smoking, stratification by the number of daily cigarettes showed a clear and striking dose-response effect, with smoking more cigarettes per day being associated with a greater reduction in infection risk ([Figure 2B](#)). Notably, even previous smokers retained some protective effect. Taken

together these findings reveal a puzzling but strikingly clear protective impact of cigarette smoking on SARS-CoV-2 susceptibility that warrants further investigation.

Differential Control of SARS-CoV-2 Infection Susceptibility and Severity

Over the full study period, 73 (6.7%) SARS-CoV-2-infected individuals were hospitalized, and 8 (0.74%) died (Supplementary Table 4). One additional participant was recorded to have likely died because of COVID-19 but could formally not be included in our study population as PCR confirmation was not available. This relatively low frequency of hospitalizations and deaths reflects the age distribution within the SHCS, with only 0.8% of PWH (82 of 10 301) aged ≥ 80 years. When stratified by age, the SHCS exhibited slightly higher hospitalization and case-fatality ratios compared with the general population (Supplementary Table 4). This modestly increased rate needs to be weighed carefully, as it may partly reflect more accurate monitoring possibilities in the SHCS than in the general population. Given the low number of hospitalized and deceased individuals, further analysis of associated parameters must be cautiously interpreted.

As seen generally in COVID-19, hospitalization in the SHCS was driven by older age and the presence of comorbid conditions (Supplementary Figure 4). We found no effect of HIV-related factors or antiretroviral medication on the risk of hospitalization. Only higher CD4⁺ T-cell values showed a trend toward a reduced risk of hospitalization (aOR, 0.62 [95% CI, .36–1.03]; $P = .07$). Notably, factors associated with infection risk—namely, living alone, smoking, and being black—had no impact on hospitalization rates. We observed a significantly lower hospitalization rate in 2021 than in 2020 (aOR, 0.48 [95% CI, .22–.95]; Supplementary Figure 4), after accounting for vaccination and other potential confounders. This effect is likely due to several factors as well as immunization, including increased SARS-CoV-2 immunity due to prior infection and the availability of SARS-CoV-2 therapeutics [33] for high-risk individuals in Switzerland in 2021.

Multiple Factors Influencing the SARS-CoV-2 Antibody Response

Because the immune system of PWH, even if successfully treated, remains at least partially impaired [36], in 2020 we included a control group composed of HU individuals with PCR-documented SARS-CoV-2 infection ($n = 257$) to investigate factors influencing the antibody response to SARS-CoV-2 infection. PWH with SARS-CoV-2 serology sampled after PCR-documented infection in 2020 ($n = 42$) were compared with HU individuals (Figure 3A). Restricting the analysis to PCR-documented infections enabled control of antibody responses for the time since infection (Supplementary Figure 11). Using multivariate regression models deriving the overall effect of potential determinants across all antigens and adjusting for age, sex, and time since PCR positivity, we found

that PWH had significantly lower SARS-CoV-2-specific antibody binding levels than HU individuals (Figure 3A and 3B and Supplementary Figure 11). Reduced antibody levels in PWH were observed across all immunoglobulin classes and antigens (Figure 3C and Supplementary Figures 12–14). A sensitivity analysis accounting for hospitalizations in the subgroup of PWH and HU individuals for whom this information was available corroborated the lower SARS-CoV-2 responses in PWH (Supplementary Figure 15).

We observed markedly lower SARS-CoV-2 IgG antibody reactivities among smokers, as also seen in response to vaccination [24, 37] (Figure 3D and 3E). Interestingly, black PWH had higher IgG antibody binding to all 3 spike antigens (RBD, S1, and S2) but not to the nucleocapsid (N) antigen, compared with white PWH (Figure 3D and 3E and Supplementary Figures 16–18). This selective up-regulation of spike antibodies is intriguing, as it may indicate a difference in immune recognition of viral antigens, depending on the race/ethnicity of the individual.

Preexisting HCoV Immunity and SARS-CoV-2 Infection

We and others reported modest protective effects of HCoV immunity on SARS-CoV-2 infection [27, 38–41]. We sought to determine the impact of prepandemic HCoV antibody titers on SARS-CoV-2 infection risk. We analyzed the S1 antigen reactivity of all 4 HCoVs in prepandemic plasma samples (collected in 2019 within the SHCS) from SARS-CoV-2-seropositive PWH ($n = 92$) and control PWH without SARS-CoV-2 infection ($n = 182$). Controls were matched for age, sex, race/ethnicity, smoking status, SHCS study center, and dates of pandemic and prepandemic plasma sample collection (Figure 4A and 4B and Supplementary Figure 18). We found that PWH with high prepandemic (2019) levels of antibody to HCoV-229E had a significantly reduced risk of a SARS-CoV-2 infection (aOR, 0.58 [95% CI, .35–.97]), whereas antibodies to the other HCoVs showed no such effect (Figure 4B). HCoV-229E was the most frequent HCoV detected in 2019 in our local virus diagnostics unit in Zurich, Switzerland (Figure 4C), suggesting that immunity to the most recent HCoV wave had the strongest impact on cross-protection against SARS-CoV-2. We next analyzed whether HCoV antibody responses in early 2020 had an impact on subsequent SARS-CoV-2 infection in 2020 or 2021, across the full study cohort. Consistent with the observed peak of HCoV-NL63 diagnoses in early 2020 (Figure 4C), we observed a significant protective effect of HCoV-NL63 antibodies (Figure 4D).

Notably, prepandemic antibody titers to HCoV (in particular, HCoV-NL63) were positively associated with higher SARS-CoV-2 antibody titers after a PCR-confirmed infection (Figure 5A and 5B). These effects were robust to adjustment for age, sex, CD4⁺ T-cell counts, smoking, race/ethnicity, and




Figure 3. Factors that influence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response. **A**, Comparison of AntiBody CORonavirus Assay (ABCORA) 5 reactivity for SARS-CoV-2 in individuals who had a positive SARS-CoV-2 polymerase chain reaction (PCR) result before serology, stratified by human immunodeficiency virus (HIV) status (42 people with HIV [PWH] and 257 HIV-uninfected [HU] individuals). Horizontal lines within violin plots correspond to the first quartile, median, and third quartile. **B**, Determinants of SARS-CoV-2 antibody response, as analyzed by a Bayesian multivariate analyses response in the combined data set consisting of Swiss HIV Cohort Study (SHCS) participants ($n = 42$) and HU individuals ($n = 257$). The plots summarize the effects across antigens (receptor-binding domain [RBD], S1, S2, and nucleocapsid [N]) but are stratified by immunoglobulin (Ig) class. Effects are adjusted for age, sex, HIV status, and the time since the positive SARS-CoV-2 PCR result (included as a cubic spline). **C**, Univariate analyses of the determinants of SARS-CoV-2 antibody response in the combined data set of SHCS participants and HU individuals. Effect sizes are calculated using a frequentist linear model adjusted for the shown variables and for the time since the positive SARS-CoV-2 PCR result, which is included as a cubic spline. Colors indicate effect size and direction. Fully covered cells indicate significant effects ($P < .05$), and small internal squares, nonsignificant effects. **D**, Bayesian multivariate analyses of the determinants of SARS-CoV-2 antibody response among SHCS participants, who had a positive SARS-CoV-2 PCR result before serology ($n = 42$). Plots summarize the effects across antigens (RBD, S1, S2, and N) but are stratified by immunoglobulin class. Effects are adjusted for age, sex, CD4⁺ T-cell count, smoking status, race/ethnicity, hospitalization, and the time since the positive SARS-CoV-2 PCR result, which is included as a cubic spline. **E**, Univariate analyses of the determinants of SARS-CoV-2 antibody responses in SHCS participants who had a positive SARS-CoV-2 PCR result before serology ($n = 42$). Effect sizes are calculated using a frequentist linear model adjusting for the shown variables and for. Colors indicate effect size and direction. Fully covered cells indicate significant effects ($P < .05$), and small internal squares, nonsignificant effects. In Panels **B** and **D**, lines correspond to 95% credible intervals. Abbreviations: LFOE, log-fold over empty; MFI, median fluorescence intensity.




Figure 4. High pre-pandemic human coronavirus (HCoV) antibody levels are associated with a lower risk of subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. **A**, Pre-pandemic HCoV S1 antibody responses among case patients (people with human immunodeficiency virus [HIV; PWH] who were polymerase chain reaction [PCR] positive; $n = 92$; green) and controls (PWH who were PCR negative; $n = 182$; yellow). Horizontal lines within violin plots correspond to the first quartile, median, and third quartile. **B**, Test positivity of the 4 HCoVs (229E, NL63, OC43, and HKU1) diagnosed in the local virus diagnostic unit by PCR by quarter year. **C**, Odds ratio (OR) of positive SARS-CoV-2 serologic results according to the level of pre-pandemic HCoV and SARS-CoV-2 serology, calculated using conditional logistic regression on the matched data comprising case patients and controls (see **A** and **B**). Only significant P values ($P < .05$) are displayed. **D**, Hazard ratios (HRs) comparing the time to a positive PCR test according to the prior (pre-pandemic and/or pandemic) HCoV level, and SARS-CoV-2 serology. The time-updated survival model is adjusted for age, sex, center, race/ethnicity, smoking status, and time of sample collection. Only significant P values ($P < .05$) are displayed. Abbreviations: Ig, immunoglobulin; LFOE, log-fold over empty; MFI, median fluorescence intensity.




Figure 5. Dissecting the cross-talk between human coronavirus (HCoV) immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responses. *A*, Impact of preexisting HCoV antibody response on individual SARS-CoV-2 antibody response after infection, analyzed using a Bayesian multivariate regression model. The model summarizes the effects across epitopes but is stratified by immunoglobulin class. Effects are adjusted for age, sex, CD4⁺ T-cell count, smoking status, race/ethnicity, hospitalization, and the time since the positive SARS-CoV-2 polymerase chain (PCR) reaction (included as a cubic spline). *B*, Univariate analyses of the determinants of SARS-CoV-2 antibody response in people with human immunodeficiency virus (HIV; PWH) with PCR-confirmed SARS-CoV-2 infection and pre-pandemic serologic data available ($n = 32$). Effect sizes are calculated using a frequentist linear model adjusted for age, sex, CD4⁺ T-cell count, smoking status, race/ethnicity, hospitalization, and the time since the positive SARS-CoV-2 PCR result (included as a cubic spline). Colors indicate effect size and direction. Fully covered cells indicate significant effects ($P < .05$), and small internal squares, nonsignificant effects. *C*, Bayesian multivariate analyses of the determinants of HCoV antibody responses sampled in 2020 among Swiss HIV Cohort Study (SHCS) participants ($n = 3496$). Plots summarize the effects across HCoV (HKU-1, OC43, NL63, 229E) but are stratified by immunoglobulin class. Effects are adjusted for age, sex, CD4⁺ T-cell count, smoking, and race/ethnicity. *D*, Univariate analyses of the determinants of HCoV antibody responses sampled in 2020 among SHCS participants ($n = 3496$). Effect sizes are calculated using a frequentist linear model. Colors indicate effect size and direction. Fully covered cells indicate significant effects ($P < .05$), and small internal squares, nonsignificant effects. Effects are adjusted for age, sex, CD4⁺ T-cell count, smoking, and race/ethnicity. Abbreviations: Ig, immunoglobulin; LFOE, log-fold over empty; N, nucleocapsid; RBD, receptor-binding domain.

hospitalization. Thus, irrespective of disease severity (as measured by hospitalization), high preexisting HCoV immunity promoted a higher antibody response to SARS-CoV-2 infection. Exploring factors associated with pre-pandemic HCoV antibody responses, we found that high CD4⁺ T-cell values were associated with overall lower HCoV antibody responses among PWH, which may indicate less frequent HCoV infections with increasing immune competence (Figure 5C and 5D

and Supplementary Figures 19 and 20). Consistent with more extended exposure to HCoVs, older age was associated with higher pre-pandemic HCoV antibody responses. Intriguingly, we found that smoking was associated with higher antibody responses to HCoV, which may be correlated with a potential protective mechanism, considering the observed lower SARS-CoV-2 infection rates among smokers. The fact that smokers mount elevated HCoV antibody levels (Figure 5D

but decreased SARS-CoV-2 antibody responses (Figure 3E) highlights fundamental differences between HCoV and SARS-CoV-2 infection biology and immune recognition that need to be resolved.

DISCUSSION

Using the potential of a systematic risk-factor screen in a large prospective cohort, our study yields several key observations relevant to understanding factors influencing SARS-CoV-2 infection in PWH and the general population. It provides new insights into the interplay between HCoV and SARS-CoV-2 immunity and supports evidence of the protective effects of preexisting HCoV immune responses [27, 38–40]. Observed lower SARS-CoV-2 antibody responses in PWH are likely attributable to the known residual immune dysfunction despite long-term suppressive ART [36], but they are not associated with increased infection rates or disease severity compared with the general Swiss population. Given the very high proportion of PWH with virologic suppression in the SHCS, this may not apply to settings with lower treatment or suppression rates.

The observed impact of living alone in the initial phases of the pandemic underline the influence of social distancing in limiting SARS-CoV-2 spread. Higher infection rates among black PWH may be due to socioeconomic differences that should be investigated, as they may result in fewer opportunities to protect oneself at the workplace and at home. In turn, fading of the effect in 2021 may be attributable to increased herd immunity [42]. Higher (IgG) spike antibody responses in black PWH may also have an underlying host genomic factor, as our group previously observed stronger and broader HIV-antibody responses among black PWH [43, 44].

An association between smoking and reduced SARS-CoV-2 infection risk has been reported in other studies but has not found wide acceptance [45, 46]. Our results support a potential impact of smoking: The effect is strong and highly robust as demonstrated through several sensitivity analyses. The extent of smoking was associated with the effect size, with heavy smokers being at the lowest risk. Future studies will be needed to unravel whether pathophysiologic effects, such as stimulation of innate defenses or down-regulation of angiotensin-converting enzyme 2 receptors, are involved in lower susceptibility to SARS-CoV-2 [47]. While we observed a protective lower risk of SARS-CoV-2 acquisition in smokers, this should not be read to mean that smoking will prevent against the virus or severe disease. Our study focuses on the initial SARS-CoV-2 waves in the absence of specific SARS-CoV-2 immunity. Later circulating variants are more fit than the initial strains, which also may outweigh the effect of smoking. It also needs to be considered that the reduced ability of smokers to mount SARS-CoV-2 antibody responses may reduce the capacity for virus clearance [17], inflicting more severe disease courses in smokers [48–50].

The current study has several limitations and important strengths. Some analyses remain inconclusive owing to limited power. This was the case for risk factors for hospitalization because of the overall small number of hospitalizations. Limited statistical power may also have hindered our ability to detect a protective effect associated with immunity to HCoVs with lower prevalence before the onset of the SARS-CoV-2 pandemic. As with all observational studies, confounding by unreported factors cannot be excluded. Despite careful data collection, some underreporting of SARS-CoV-2 infection remains possible, and false-negative serologic tests cannot be accounted for. Despite these limitations, our study demonstrates the power of observational cohorts to achieve a comprehensive assessment of the drivers of COVID-19 in PWH and beyond. Our cohort screen confirms that SARS-CoV-2 vaccination has a clear protective effect in PWH on ART.

The depth of our analysis allowed us to identify several factors associated with SARS-CoV-2 infection risk. Overall, we found it most intriguing that 2 unrelated factors affecting the respiratory milieu, namely prior HCoV infection and smoking, had strong protective effects against SARS-CoV-2 acquisition. This warrants future in-depth analyses of the protective mechanisms in the respiratory mucosa to potentially implicate these factors in antiviral defense.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online (<http://jid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. The authors thank all patients, physicians, and nurses associated with the participating cohorts. Figure 1A was created with Biorender.com, Microsoft PowerPoint, and icons from thenounproject.com (icon 5159916 from Studio 365; icon 1586848 from Kelsey Armstrong; icon 2049584 from Vectors Market; icon 1997675 from Oleksandr Panasovskiy).

Author contributions. Study conception and design: I. A. A., A. H., C. P., H. F. G., A. T., and R. D. K. Data collection: I. A. A., A. H., M. S., C. P. Analysis and interpretation of results: I. A. A., A. H., M. S., C. P., H. F. G., A. T., and R. D. K. Draft manuscript preparation: I. A. A., A. H., M. S., C. P., H. F. G., A. T., and R. D. K. All authors reviewed the results and approved the final version of the manuscript.

Members of the SHCS. I. A. Abela, K. Aebi-Popp, A. Anagnostopoulos, M. Battegay, E. Bernasconi, D. L. Braun, H. C. Bucher, A. Calmy, M. Cavassini, A. Ciuffi,

G. Dollenmaier, M. Egger, L. Elzi, J. Fehr, J. Fellay, H. Furrer, C. A. Fux, H. F. Günthard (president of the SHCS), A. Hachfeld, D. Haerry (deputy of the “Positive Council”), B. Hasse, H. H. Hirsch, M. Hoffmann, I. Hösli, M. Huber, D. Jackson-Perry (patient representatives), C. R. Kahlert (chair of the Mother & Child Substudy), L. Kaiser, O. Keiser, T. Klimkait, R. D. Kouyos, H. Kovari, K. Kusejko (head of Data Centre), N. Labhardt, K. Leuzinger, B. Martinez de Tejada, C. Marzolini, K. J. Metzner, N. Müller, J. Nemeth, D. Nicca, J. Notter, P. Paioni, G. Pantaleo, M. Perreau, A. Rauch (chair of the Scientific Board), L. Salazar-Vizcaya, P. Schmid, R. Speck, M. Stöckle (chair of the Clinical and Laboratory Committee), P. Tarr, A. Trkola, G. Wandeler, M. Weisser, and S. Yerly.

Data sharing. Deidentified individual-level participant data are available on reasonable request. The data sets generated and/or analyzed during the current study are not publicly available, since they are subject to national data protection laws and restrictions imposed by the ethics committee to ensure data privacy of the study participants (<http://www.shcs.ch/294-open-data-statement-shcs>). The code for the analysis is archived at the University Hospital of Zurich. Requests for data sharing can be directed to the corresponding authors.

Financial support. This work was supported by the Swiss National Science Foundation (grant 31CA30_196906 to H. F. G., A. T., and R. D. K.), SHCS Project 870, the SHCS Research Foundation, the Gilead COVID-19 RFP Research Program (COMMIT grant IN-SW-983-6078 to H. F. G., A. T., and R. D. K.); and the Promedica Foundation (research grant to I. A. A.). The SHCS was supported by the Swiss National Science Foundation (grant 33CS30_201369).

Potential conflicts of interest. I. A. A. has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences, and a grant from Promedica Foundation. M. C.’s institution received research grants and fees for expert opinion given to Gilead, MSD and ViiV. D. L. B. reports honoraria paid to himself for advisory boards from the companies AstraZeneca, Pfizer, Gilead, MSD and ViiV. H. F. G. reports honoraria from Gilead Sciences, Merck, ViiV, GSK, Janssen, Johnson and Johnson, and Novartis for serving on data and safety monitoring and/or advisory boards; a travel grant from Gilead Sciences; and grants from the Swiss National Science Foundation (SNSF), the SHCS, the Yvonne Jacob Foundation, and the National Institutes of Health, as well as unrestricted research grants from Gilead Sciences, all paid to the author’s institution. A. T. has received honoraria from Roche Diagnostics for consultant activity; grants from the SNSF, the Swiss HIV Cohort Study, and the Pandemiefonds of the UZH Foundation; and unrestricted research grants from Gilead Sciences. R. D. K. has received grants from SNSF, the National Institutes of Health, and

Gilead Sciences. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Aldridge RW, Yavlinsky A, Nguyen V, et al. SARS-CoV-2 antibodies and breakthrough infections in the virus watch cohort. *Nat Commun* **2022**; 13:4869.
2. The RESPOND Study Group. How to RESPOND to modern challenges for people living with HIV: a profile for a new cohort consortium. *Microorganisms* **2020**; 8:1164.
3. Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: the Swiss HIV Cohort Study (SHCS). *Int J Epidemiol* **2022**; 51:33–4j.
4. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *Lancet HIV* **2021**; 8:e24–32.
5. Inciarte A, Gonzalez-Cordon A, Rojas J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. *AIDS* **2020**; 34:1775–80.
6. Kusejko K, Chammartin F, Smith D, et al. Developing and testing a Corona Vaccine tRIAL pLatform (COVERALL) to study COVID-19 vaccine response in immunocompromised patients. *BMC Infect Dis* **2022**; 22:654.
7. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* **2021**; 19:141–54.
8. Chudasama YV, Zaccardi F, Gillies CL, et al. Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K. *BMC Infect Dis* **2021**; 21:908.
9. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. *Cell Metab* **2021**; 33:479–98.
10. Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. *Sci Rep* **2021**; 11:6283.
11. Nomah DK, Reyes-Uruena J, Diaz Y, et al. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. *Lancet HIV* **2021**; 8:e701–10.
12. Joy M, Hobbs FR, Bernal JL, et al. Excess mortality in the first COVID pandemic peak: cross-sectional analyses of

- the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. *Br J Gen Pract* **2020**; 70:e890–8.
13. Jassat W, Cohen C, Tempia S, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. *Lancet HIV* **2021**; 8:e554–67.
 14. Kohler I, Kouyos R, Bianchi M, et al. The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. *AIDS* **2015**; 29:1803–10.
 15. Tian Y, Hua W, Wu Y, et al. Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis. *Front Immunol* **2021**; 12:745541.
 16. Portillo V, Fedeli C, Ustero Alonso P, et al. Impact on HIV-1 RNA levels and antibody responses following SARS-CoV-2 vaccination in HIV-infected individuals. *Front Immunol* **2021**; 12:820126.
 17. Marconato M, Abela IA, Hauser A, et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. *J Clin Invest* **2022**; 132:e158190.
 18. Ruffieux Y, Lemsalu L, Aebi-Popp K, et al. Mortality from suicide among people living with HIV and the general Swiss population: 1988–2017. *J Int AIDS Soc* **2019**; 22:e25339.
 19. Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. *AIDS* **2017**; 31:427–36.
 20. Lombardi F, Ricci R, Belmonti S, et al. Seroprevalence of SARS-CoV-2 antibodies in HIV-infected patients in Rome, Italy during the COVID-19 outbreak. *Diagnostics (Basel)* **2021**; 11:1154.
 21. Berenguer J, Diez C, Martin-Vicente M, et al. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV research network cohort. *Clin Microbiol Infect* **2021**; 27:1678–84.
 22. Wolter N, Tempia S, von Gottberg A, et al. Seroprevalence of severe acute respiratory syndrome coronavirus 2 after the second wave in South Africa in human immunodeficiency virus-infected and uninfected persons: a cross-sectional household survey. *Clin Infect Dis* **2022**; 75:e57–68.
 23. Shapiro AE, Bender Ignacio RA, Whitney BM, et al. Factors associated with severity of COVID-19 disease in a multi-center cohort of people with HIV in the United States, March–December 2020. *J Acquir Immune Defic Syndr* **2022**; 90:369–76.
 24. Chammartin F, Kusejko K, Pasin C, et al. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV. *AIDS* **2022**; 36:1465–8.
 25. Chammartin F, Griessbach A, Kusejko K, et al. Bridging the gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1. *AIDS* **2023**; 38:217–22.
 26. Swiss National Science Foundation Longitudinal studies. <http://www.snf.ch/en/funding/programmes/longitudinal-studies/Pages/default.aspx#Currently%20supported%20longitudinal%20studies>. Accessed 20 January 2024.
 27. Abela IA, Pasin C, Schwarzmueller M, et al. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. *Nat Commun* **2021**; 12:6703.
 28. Swiss Federal Office of Public Health. COVID-19 Switzerland, coronavirus dashboard. <https://www.covid19.admin.ch/en/overview>. Accessed 12 August 2022.
 29. Therneau T, Crowson C, Atkinson E. Using time dependent covariates and time dependent coefficients in the Cox model. <https://cran.r-project.org/web/packages/survival/vignettes/timedep.pdf>. Accessed 21 January 2024.
 30. R Core Team. R: a language and environment for statistical computing. <https://www.R-project.org/>. Accessed 21 January 2024.
 31. Ong SYQ, Flyamer IM, Bickmore WA, Biddie SC. From bedside to bench: regulation of host factors in SARS-CoV-2 infection. *Exp Mol Med* **2021**; 53:483–94.
 32. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. *Nat Rev Microbiol* **2022**; 20:270–84.
 33. Swiss Federal Office of Public Health. Coronavirus: Neuigkeiten und Anpassungen. <https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/information-fuer-die-aerzteschaft/neuigkeiten-und-anpassungen.html>. Accessed 31 December 2021.
 34. Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. *Ann Intern Med* **2020**; 173:536–41.
 35. Labhardt ND, Smit M, Petignat I, et al. Post-exposure lopinavir-ritonavir prophylaxis versus surveillance for individuals exposed to SARS-CoV-2: the COPEP pragmatic open-label, cluster randomized trial. *EclinicalMedicine* **2021**; 42:101188.
 36. Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. *Semin Immunol* **2021**; 51:101471.
 37. Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. *Diabetes Metab Res Rev* **2022**; 38:e3465.
 38. Ortega N, Ribes M, Vidal M, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. *Nat Commun* **2021**; 12:4740.

39. Lavell AHA, Sikkens JJ, Edridge AWD, et al. Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. *iScience* **2022**; 25:105105.
40. Loyal L, Braun J, Henze L, et al. Cross-reactive CD4⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. *Science* **2021**; 374:eabh1823.
41. Stoddard CI, Sung K, Ojee E, et al. Distinct antibody responses to endemic coronaviruses pre- and post-SARS-CoV-2 infection in Kenyan infants and mothers. *Viruses* **2022**; 14: 1517.
42. Verburgh ML, Boyd A, Wit F, et al. Similar risk of severe acute respiratory syndrome coronavirus 2 infection and similar nucleocapsid antibody levels in people with well-controlled human immunodeficiency virus (HIV) and a comparable cohort of people without HIV. *J Infect Dis* **2022**; 225:1937–47.
43. Kadelka C, Liechti T, Ebner H, et al. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. *J Exp Med* **2018**; 215: 1589–608.
44. Rusert P, Kouyos RD, Kadelka C, et al. Determinants of HIV-1 broadly neutralizing antibody induction. *Nat Med* **2016**; 22:1260–7.
45. Paleiron N, Mayet A, Marbac V, et al. Impact of tobacco smoking on the risk of COVID-19: a large scale retrospective cohort study. *Nicotine Tob Res* **2021**; 23:1398–404.
46. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 10). *Qeios*. doi:10.32388/UJR2AW.11.
47. Tanimoto K, Hirota K, Fukazawa T, et al. Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal. *Sci Rep* **2021**; 11:16629.
48. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). *Addiction* **2021**; 116:1319–68.
49. Clift AK, von Ende A, Tan PS, et al. Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK biobank cohort. *Thorax* **2022**; 77:65–73.
50. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. *J Med Virol* **2021**; 93:1045–56.